Verastem, Inc.
Develops cancer medicines targeting the RAS/MAPK pathway, with an approved therapy for ovarian cancer.
VSTM | US
Overview
Corporate Details
- ISIN(s):
- US92337C2035
- LEI:
- Country:
- United States of America
- Address:
- 117 KENDRICK STREET, 2494 NEEDHAM
- Website:
- https://www.verastem.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focused on developing and commercializing novel medicines for cancer treatment. The company's clinical program centers on small molecule inhibitors that target the critical RAS/MAPK signaling pathway, which is associated with many aggressive and recurring cancers. A key achievement for Verastem is its FDA-approved combination therapy for KRAS-mutant recurrent low-grade serous ovarian cancer. Through a portfolio of ongoing trials and strategic collaborations, the company aims to address urgent medical needs for patients with difficult-to-treat malignancies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
Automate Your Workflow. Get a real-time feed of all Verastem, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Verastem, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Verastem, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
